Different Medications for Hypogonadotropic Hypogonadism.

Area of Science:

• Pediatric Endocrinology
• Reproductive Medicine
• Adolescent Health

Background:

• Delayed puberty (DP) in boys is defined as the absence of sexual maturation by age 14.
• Causes of DP are diverse, including constitutional delay (CDP), hypogonadotropic hypogonadism (HH), and hypergonadotropic hypogonadism.
• Accurate diagnosis is crucial for effective treatment selection.

Purpose of the Study:

• To review the causes and management strategies for delayed puberty in boys.
• To highlight the importance of differential diagnosis in guiding therapeutic interventions.
• To discuss current and emerging treatment options for DP.

Main Methods:

• Review of existing literature on delayed puberty in boys.
• Classification of DP causes into reversible and irreversible categories.
• Analysis of therapeutic approaches based on underlying etiology.

Main Results:

• Constitutional delay of puberty (CDP) is the most frequent cause (63%).
• Functional hypogonadotropic hypogonadism (HH) accounts for 20% of cases.
• Treatment strategies range from expectant management in CDP to long-term hormone replacement (testosterone, gonadotropins, GnRH) for hypogonadal states.

Conclusions:

• Effective management of DP requires accurate diagnosis to differentiate causes.
• Therapeutic options include watchful waiting, short-term testosterone for psychological support in CDP, and long-term hormonal treatments for hypogonadism.
• Novel agents like kisspeptin agonists show promise for future DP treatment.